Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)

PURPOSE: This phase II study evaluated the impact of adding ribociclib to maintenance endocrine therapy (ET) treatment of physicians’ choice following the first palliative chemotherapy in pre- and post-menopausal women with hormone receptor positive (HR+)/human epidermal growth factor 2 negative (HE...

Descripción completa

Detalles Bibliográficos
Autores principales: Decker, Thomas, Lüdtke-Heckenkamp, Kerstin, Melnichuk, Luidmila, Hirmas, Nader, Lübbe, Kristina, Zahn, Mark-Oliver, Schmidt, Marcus, Denkert, Carsten, Lorenz, Ralf, Müller, Volkmar, Zahm, Dirk-Michael, Mundhenke, Christoph, Bauer, Stefan, Thill, Marc, Seropian, Peter, Filmann, Natalie, Loibl, Sibylle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507224/
https://www.ncbi.nlm.nih.gov/pubmed/37690320
http://dx.doi.org/10.1016/j.breast.2023.08.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507224/
https://www.ncbi.nlm.nih.gov/pubmed/37690320
http://dx.doi.org/10.1016/j.breast.2023.08.007

Ejemplares similares